In this study we evaluated the mechanisms of resistance that may emerge by targeting EGFR-T790M in NSCLC and identified NF-κB as key player in adaptive and reversible resistance to the novel mutant selective EGFR inhibitor CNX-2006. This evidence concerns the gene EGFR and non-small cell lung carcinoma.